Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Programmed Cell Death
51%
Gene Expression
46%
DNA Repair
45%
Aedes albopictus
39%
Ribonucleotide Reductase
34%
Cell Count
28%
Gene Expression Profiling
28%
Tumor Suppressor Gene
27%
Peptide Sequence
27%
Isoform
27%
Amino Acid
26%
Downregulation
25%
Clinical Trial
24%
Tumor Suppressor Protein
22%
Ultraspiracle
22%
Gene Amplification
21%
Wild Type
20%
Cell Lysate
20%
RNA
20%
C-Terminus
20%
Reverse Transcription Polymerase Chain Reaction
20%
P53
20%
Tumor Progression
18%
Antisense
17%
Fibrinogen
17%
Apoptotic Protease Activating Factor
17%
cDNA Cloning
17%
Phosphoprotein
17%
Plasmid
17%
Copy-Number Variation
17%
Caspase
17%
Erlotinib
17%
Promoter Region
17%
Gene Therapy
17%
Cisplatin
17%
Hydroxycarbamide
17%
Mass Spectrometry
17%
Autophagy
17%
Nucleic Acid
17%
GTPase
17%
Telomerase Reverse Transcriptase
17%
Ribosomal Protein
17%
Protein Characterization
17%
Amplicon Sequencing
17%
Protein-Protein Interaction
17%
Phenotypic Plasticity
17%
Histidine
17%
Enhancer Region
17%
Epidermal Growth Factor Receptor
17%
Keyphrases
Circulating Tumor Cells
51%
Metastatic Breast Cancer
36%
Microcavity Array
35%
Parsortix
34%
Aedes Albopictus
24%
Mosquito Cells
22%
Human Lung Cancer Cells
18%
Gene Expression Profiling
18%
Gene Expression
17%
Promoter Activity
17%
Therapy Response
17%
Apoptotic Pathway
17%
Apoptotic Protease Activating factor-1
17%
Tumor Suppression
17%
NPRL2
17%
Human Telomerase Reverse Transcriptase Promoter
17%
Copy number Variation Detection
17%
Amino Acid Deletion
17%
Non-small Cell Lung Cancer Cells
17%
AP-2
17%
Poor Response
17%
20-hydroxyecdysone
17%
Ultraspiracle
17%
Newly Diagnosed
17%
Tumor-specific
17%
Multicenter Clinical Trial
17%
Functional Gene Transfer
17%
TUSC2
17%
Response to Therapy
17%
FUS1
17%
Phenotypic Plasticity
17%
Ribonucleotide Reductase
17%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
17%
Enhancer-binding Protein
17%
Ribosomal Protein P0
17%
Murine Double Minute 2 (MDM2)
17%
Co-expression
17%
DNA Repair Pathways
17%
HER2-overexpressing Breast Cancer
17%
Synergize
17%
Trastuzumab Deruxtecan (T-DXd)
17%
HER2-targeted Therapy
17%
Therapeutic Target
17%
Peptide Pools
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Quantitative PCR
9%
HER2+ Breast Cancer
9%
Circulating Tumor Cell Count
9%
Lung Cancer Cells
8%
Amino Acids
7%
Medicine and Dentistry
Circulating Tumor Cell
68%
Lung Cancer
47%
Messenger RNA
38%
Non Small Cell Lung Cancer
38%
DNA Repair
34%
Tumor Suppressor Gene
27%
Cancer Cell
24%
Protein Expression
23%
Clinical Trial
22%
Gene Expression Profiling
21%
Metastatic Breast Cancer
20%
Nanoparticle
19%
Neoplasm
17%
Ras Signaling
17%
Treatment Response
17%
Cancer Inhibition
17%
Rho Guanine Nucleotide Binding Protein
17%
1,2 Dioleoyl 3 Trimethylammoniopropane
17%
Clinical Study
17%
Ecdysterone
17%
Untranslated Region
17%
Histidine
17%
Gene Transfer
17%
Unscheduled DNA Synthesis
17%
Breast Cancer
17%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
17%
Trastuzumab Deruxtecan
17%
Malignant Neoplasm
15%
Gene Expression
11%
Real-Time Polymerase Chain Reaction
11%
Blood Donor
11%
In Vitro
11%
Programmed Cell Death
10%
Cancer Cell Line
10%
Cell Signaling Pathway
9%
Gene Therapy
8%
Plasmid
8%
Reverse Transcription Polymerase Chain Reaction
8%
Mucin 1
7%
Cell Size
7%
Fluorescence in Situ Hybridization
7%
Lung Cancer Cell Line
6%
Lung
6%
RNAI
6%
Small Interfering RNA
6%
Propane
6%
Metastatic Carcinoma
6%
Hazard Ratio
5%
MCF-7
5%
Thymidine
5%
